CLARIS LIFESCIENCES LTD. News and Updates

Keep track of all breaking news on CLARIS LIFESCIENCES LTD. from all sources in a single place.

13 Mar 2018

Claris Lifesciences shares to delist from BSE on March 22

Business Standard

Promoter Arjun Handa has bought back shares from existing shareholders and now holds 96 per cent in the soon-to-be delisted entity

Claris Lifesciences to delist from March 22

Business Line | 12 Mar 2018 1 more

CLARIS LIFESCIENCES LTD.

09 Feb 2018

Claris Lifesciences: Delisting offer begins

Business Line

The delisting offer to the shareholders of Claris Lifesciences will open on Monday at the BSE. The company, which fixed the floor price at 351.60, plans to buy

CLARIS LIFESCIENCES LTD.

07 Dec 2017

Claris Lifesciences extends fall after board approves delisting proposal

Business Standard

The stock was down 3% to Rs 352, falling 6% from its early morning high of Rs 374 on the BSE.

CLARIS LIFESCIENCES LTD.

02 Dec 2017

Claris Life promoter seeks delisting of shares

Business Line

Claris Lifesciences today said it has received a letter from the promoter Athanas Enterprise Pvt Ltd to consider delisting of shares of the pharma company from the stock exchange. The...

CLARIS LIFESCIENCES LTD.

12 Oct 2017

Claris studying options to distribute Rs 2,077 cr to its shareholders

Business Standard

Shares of Claris Lifesciences today closed at Rs 335.70 on the BSE

CLARIS LIFESCIENCES LTD.

22 Sep 2017

Claris completes sale of its remaining 20% stake in Otsuka JV for Rs 130 cr

Business Standard

Ahmedabad-headquartered injectables player Claris Lifesciences has completed the sale of its remaining 20 per cent stake in Otsuka Pharmaceutical India Private Ltd (OPIPL), the joint venture with Otsuka Pharmaceutical Factory Inc and Mitsui & Co Ltd, to Otsuka for a consideration of $ 20 million (Rs 130 crore). Otsuka held 60 per cent in thr JV, while Mitsui held 20 per cent and the remaining 20 per cent was with Claris. Claris Board had approved the decision in May this year to divest its entire stake in OPIPL.Earlier, in December 2012, Claris Lifesciences had entered into a joint venture with Japan's Otsuka Pharmaceutical Factory Inc and Mitsui & Co Ltd for its infusion business in India and emerging markets. The business was valued at Rs 1313 crore at that time, and Claris had received total cash consideration of Rs 1,050 crore over multiple agreements. Claris had transfered the common solutions, anti-infectives, plasma volume expanders and parenteral nutrition therapies ..

CLARIS LIFESCIENCES LTD.

28 Jul 2017

Claris sells global generic injectables business to Baxter for $625 mn

Business Line

City-based pharma player, Claris Lifesciences Ltd, said the company has completed the sale of its Global Generic Injectables Business to Baxter International Inc (USA) for an enterprise value of...

CLARIS LIFESCIENCES LTD.

27 Jul 2017

Today's Pick (English): Claris Lifesciences

Business Line

Claris Lifesciences (390.8)

Business Line | 27 Jul 2017 1 more

CLARIS LIFESCIENCES LTD.

01 Jun 2017

Not received any observation from USFDA audit: Claris

Business Line

Claris Lifesciences underwent an audit by the USFDA for pharmacovigilance in the last week of May and has not received any observation. Claris Lifesciences along with its wholly-owned subsidiary...

CLARIS LIFESCIENCES LTD.

18 Apr 2017

FIPB clears Claris Lifesciences' bid to sell global generic injectables

livemint

Claris Lifesciences has a total of 40 abbreviated new drug applications filed with the US FDA, of which 16 have been approved

Is CLARIS LIFESCIENCES LTD. worth buying?

8 Votes:

Buy 87.5%

Sell 12.5%